The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy

It is a prospective, non-randomized, single-arm cohort study. A total of 10 patients will be included in this study. Based on standardized treatment, the treatment of bioartificial liver device will be applied 48-72 hours after extensive hepatectomy. The bioartificial liver device consists of clinical-grade human-induced hepatocytes (hiHep) generated from human fibroblasts via transdifferentiation. In order to evaluate the security and effectiveness of the device, liver function, liver volume, the incidence of liver failure and other results will be analyzed.

Trial Details

NCT ID
NCT05035108
Phase
EARLY_PHASE1
Sponsor
Sir Run Run Shaw Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • hiHep bioartificial liver therapy
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Diagnosed as liver cancer, hepatolithiasis, benign liver tumor, with clear indications for liver resection;
  • Liver function Child A-B;
  • There is no contraindication to surgery for cardiopulmonary function;
  • The expected remaining liver volume/standard liver volume is less than 50%;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →